EKF Diagnostics will be exhibiting its range of molecular diagnostics products supporting personalized medicine in cancer at the 2015 American Society of Clinical Oncology (ASCO) annual meeting, 29th May to 2nd June, McCormick Place, Chicago, Illinois.

Here 30,000 oncology professionals from around the world will be brought together to discuss the very latest in treatment modalities, therapies and research in the field, in order to apply this knowledge to enhance cancer patient care.

EKF subsidiary, Selah Genomics’ newly introduced PrecisionPath™ next generation sequencing (NGS) technology cancer test will be a key focus on Booth #19141.

This first commercially available NGS panel molecular test priced under US$1000, which was recently launched in partnership with Greenville Health systems (GHS), paves the way for accessible, low-cost personalized medicine in colon cancer.

At ASCO, key personnel from Selah Genomics will be on hand to discuss how PrecisionPath™ can help oncologists select the most effective treatment options for a patient based on the specific molecular profile of their tumor. 

Also to be exhibited on the EKF booth, will be EKF Molecular Diagnostics’ PointMan™ DNA enrichment kits for the ultra-low level detection of cancer gene mutations in both tissue and blood biopsies.

These include kits for enrichment of cancer biomarkers, such as KRAS, BRAF,EGFR, JAK2 and ESR1. Notably, data has recently been presented which identifies PointMan™ technology as an easy and useful method for non-invasively determining plasma EGFR T790M mutation status in late stage lung cancer patients [1].

Reference:

Nishikawa, S. et al. Non-invasive analysis for T790M mutations of EGFR using a selective amplification method. American Association for Cancer Research (AACR) Annual Meeting 2015.